ECE2015 Eposter Presentations Calcium and Vitamin D metabolism (96 abstracts)
Evaluation of the effect of bisphosphonate therapy of postmenopausal osteoporosis using Dolga index
Jovanka Novakovic-Paro 1 , Tijana Icin 1 , Dragana Tomic-Naglic 1 , Milena Mitrovic 1 , Radoslav Pejin 1 , Milan Dolga 3 , Ivana Bajkin 1 , Bojan Vukovic 2 , Damir Benc 1 , Djordje Popovic 1 , Andrijana Milankov 1 , Milica Medić-Stojanoska 1 & Branka Kovačev-Zavisic 1
1Medical Faculty, Clinic of Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Vojvodina, University of Novi Sad, Novi Sad, Serbia; 2Medical Faculty, Emergency Center, Clinical Centre of Vojvodina, University of Novi Sad, Novi Sad, Serbia; 3Smart Line Agency, Novi Sad, Serbia.
Introduction: Bisphosphonates are commonly used in the treatment of osteoporosis. The aim was to determine the effect of bisphosphonate therapy for osteoporosis on bone mineral density (BMD) depending on the Dolga index.
Materials and methods: The study included 36 postmenopausal women with osteoporosis. BMD was measured by DXA of the spine and hip before treatment and 2 years after starting bisphosphonate therapy. Parameters of bone turnover: osteocalcin and beta crosslaps were measured before treatment. On the basis of these values was calculated Dolga index. The Dolga index expresses excessive suppression of bone resorption and excessive suppression of the entire remodelling if the value obtained above 0.
Results: Average age of the respondents was 62.94±8.49 years, with a mean BMI 25.60±3.68 kg/m2. After 2 years of therapy, a statistically significant difference in the parameters of bone remodelling and BMD (OC: 37.05±14.36 vs 17.95±5.62 ng/ml, P<0.05; beta crosslaps: 658.37±264.57 vs 173.0±96.92 pg/ml, P<0.05; L1–4 BMD: 0.813±0.010 vs 0.862±0.132 g/cm2, total hip: 0.793±0.08 vs 0.826±0 07 g/cm2; hip neck: 0.764±0.08 vs 0.07±0.788 g/cm2. Using Dolga index, statistically significant improvement in spine and hip BMD were obtained in the group that did not have excessive suppression of bone resorption and bone remodelling. (L1–4: 0.803±0.007 vs 0.842±0.009 g/cm2, P<0.05; total hip: 0.792±0.007 vs 0.825±0.008 g/m2, P<0.05; hip neck: 0.780±0.005 vs 0.802±0.006 g/cm2, P<0.05).
Conclusions: The use of bisphosphonate therapy leads to improvements in BMD with primary effect on bone resorption affecting the overall bone remodelling. The test results demonstrate the usefulness of the application of Dolga index in choosing patients with postmenopausal osteoporosis for the application of bisphosphonate therapy in order to achieve the best therapeutic effect. Continued research is ongoing on a larger sample in order to confirm the results, make new conclusions and recommendations for the treatment of postmenopausal osteoporosis bisphosphonate therapy.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more